For a review, researchers wanted to locate and debate current studies on the prevention and treatment of systemic allergic responses to allergen immunotherapy (AIT). AIT-related deaths may be on the decline. Screening asthma patients before AIT and adjusting doses during pollen season may help to reduce systemic response rates. When compared to cluster build-up protocols with single-allergen SCIT, cluster build-up techniques with multi allergen SCIT may increase the risk of systemic responses. Sublingual immunotherapy (SLIT) trials corroborate the method’s low rates of systemic responses, even with quick build-up schedules. There are too few patients in studies of newer kinds of AIT (intralymphatic, epicutaneous, recombinant allergens) to develop credible systemic response risk estimates. It is possible that high-grade delayed systemic responses to AIT are less common than previously documented.
Recent research raises confidence in risk estimates for systemic responses to AIT, proposes helpful methodologies for predicting systemic reactions to AIT, and gives strategies for preventing systemic reactions.